Caris Life Sciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
CAI$24.43-4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)
| (amounts in thousands, except share and per share data) | Three Months Ended September 30, | Nine Months Ended September 30, | ||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue: | ||||
| Molecular profiling services | $262,707 | $207,587 | $725,760 | $484,593 |
| Pharma research and development services | 12,651 | 9,246 | 29,483 | 34,554 |
| Total revenue | 275,358 | 216,833 | 755,243 | 519,147 |
| Costs and operating expenses: | ||||
| Cost of Services - Molecular profiling services | 89,172 | 66,980 | 243,383 | 193,195 |
| Cost of Services - Pharma research and development services | 3,901 | 2,347 | 8,630 | 7,698 |
| Selling and marketing expense | 59,853 | 41,267 | 158,661 | 123,355 |
| General and administrative expense (see note 9) | 69,278 | 51,973 | 195,534 | 168,458 |
| Research and development expense | 33,838 | 21,624 | 97,511 | 69,739 |
| Total costs and operating expenses | 256,042 | 184,191 | 703,719 | 562,445 |
| Income (Loss) from operations | 19,316 | 32,642 | 51,524 | (43,298) |
| Other expense, net: | ||||
| Interest income | 6,332 | 7,360 | 19,985 | 9,482 |
| Interest expense | (9,249) | (13,507) | (31,286) | (45,497) |
| Changes in fair value of financial instruments | — | (2,081) | — | (52,285) |
| Other income (expense), net | 475 | (89) | (24,607) | (18,447) |
| Total other expense, net | (2,442) | (8,317) | (35,908) | (106,747) |
| Income (Loss) before income taxes | 16,874 | 24,325 | 15,616 | (150,045) |
| Income tax expense | (1,624) | — | (1,513) | — |
| Net income (loss) | 15,250 | 24,325 | 14,103 | (150,045) |
| Other comprehensive income (loss), net of tax: | ||||
| Unrealized loss on available-for-sale securities | (153) | — | (408) | — |
| Foreign currency translation adjustments | (481) | 79 | (633) | 538 |
| Comprehensive income (loss) | 14,616 | 24,404 | 13,062 | (149,507) |
| Net income (loss) attributable to common shareholders: | ||||
| Net income (loss) | 15,250 | 24,325 | 14,103 | (150,045) |
| Deemed dividend from Series D redeemable convertible preferred stock | — | — | — | (384,436) |
| Adjustments of redeemable convertible preferred stock to redemption value | — | — | — | (85,433) |
| Net income (loss) attributable to common shareholders | $15,250 | $24,325 | $14,103 | $(619,914) |
| Net income (loss) per share attributable to common shareholders: | ||||
| Basic | $0.05 | $0.09 | $0.05 | $(4.83) |
| Diluted | $0.05 | $0.08 | $0.05 | $(4.83) |
| Weighted-average shares used in computing net income (loss) per share attributable to common shareholders: | ||||
| Basic | 283,894,498 | 282,099,073 | 283,118,633 | 128,447,673 |
| Diluted | 295,140,869 | 297,211,838 | 294,241,534 | 128,447,673 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.